Skip to content
  • Products & Services Offered
  • Clinical Data & Research
  • Media
  • About Us
  • Contact Us
Menu
  • Products & Services Offered
  • Clinical Data & Research
  • Media
  • About Us
  • Contact Us

Giving a Voice to Silent Endometriosis

Over 300 fertility centers around the US and globally depend on Cicero Diagnostics to help them with their most challenging patients

Products & Services Offered

ReceptivaDx™ – For Unexplained Infertility, Failed IMPLANTATION & Recurrent Pregnancy Loss

ReceptivaDx represents a new generation of testing to detect defects on the uterine lining responsible for unexplained infertility, implantation failure and recurrent pregnancy loss. Using proprietary biochemical markers, endometrial tissue (obtained via biopsy) can now be analyzed without the need for invasive surgery to detect inflammation most often associated with asymptomatic endometriosis.

BCL6, the primary marker of the ReceptivaDx test has been demonstrated to have 93% sensitivity and 96% specificity in the detection of endometriosis. The condition of endometriosis is believed to be the biggest culprit behind the majority of unexplained infertility cases after all other male and female factors have been ruled out.

The declining use of laparoscopy in the last 15 years has made the availability of the BCL6 marker more important than ever. The ability to measure BCL6 via the ReceptivaDx test provides a reliable, affordable and much less invasive method for detection, providing new hope and new treatment pathways to pregnancy in the most challenging fertility cases.

In addition to being recognized a marker of inflammation linked to endometriosis, BCL6 has also been found to play a key role in progesterone resistance. The hormone progesterone is vital in pregnancy to create a safe environment for a developing embryo. Since BCL6 inhibits progesterone when over-expressed, this causes a less viable endometrial environment and the inability to protect the developing embryo throughout pregnancy.

To learn more about ReceptivaDx, click the button below.

Learn More
KEY FACTS ABOUT RECEPTIVADX (BCL6) RESULTS
Over 75% of women with unexplained infertility tested positive for BCL6 in published clinical studies
The incidence rate of positive results increased to 83% in women with multiple IVF transfer failures and/or a history of multiple miscarriages
Women testing positive for ReceptivaDx (BCL6) were 5 times less likely to conceive than women testing negative
If positive for BCL6, studies demonstrated success rates approaching 60% after receiving treatment (either hormone suppression therapy or surgery).
Left untreated, women testing positive for ReceptivaDx (BCL6) had less than 12% success in future pregnancy attempts

Clinical Data & Research

Extensive published clinical data is available to support the use of ReceptivaDx in the clinical setting for assistance in unexplained infertility.

Click Here for Full Publication List

Cicero Diagnostics has ongoing research via an NIH Commercial Grant Awarded in 2019 to further evaluate and develop testing mechanisms related to markers associated with endometriosis, unexplained infertility, failed IVF and recurrent pregnancy loss.

Current Academic Affiliations
Wake Forest University

Dept of Ob-Gyn – Reproductive Medicine Winston Salem, NC

Stanford University

Department of Reproductive Medicine Palo Alto, CA

University of North Carolina at Chapel Hill

Dept of Ob-Gyn Reproductive Medicine Raleigh, NC

Clemson University

Clemson, SC

Clinical and Research Consultants
Pathology Consultants

Dr. David Schammel, M.D. – Pathologist
Greenville, SC

Cicero Diagnostics Shared Experience Program

In 2019, Cicero Diagnostics established a collaborative network of high-volume referring clients across the US. As part of our “Shared Experience Program” , these participating centers will work with Cicero Diagnostics to provide treatment and outcome data based on patients testing positive for ReceptivaDx markers. Cicero Diagnostics published its first set of outcomes data on over 140 patients from seven major centers in April of 2020. This data supported the previous published studies showing the success of the ReceptivaDx markers. By the end of 2021, Cicero Diagnostics had performed testing on over 10,000 patients representing 350 centers worldwide.

Cicero Diagnostics Shared Experience Participating Fertility Centers
Aimee Eyvazzadeh, M.D
San Ramon, CA
NYU Langone Fertility
New York City, NY
CCRM – San Francisco
Menlo park, CA
CCRM – New York
New York City, NY
Central Coast Fertility
San Luis Obispo, CA
Tennessee Reproductive Medicine
Chattanooga, TN
Fresno Fertility
Fresno, CA
Nashville Fertility
Nashville, TN
Fertility Centers of Illinois
Chicago, IL
UNC Fertility
Raleigh, NC
Heartland Center for Reproductive Medicine
Omaha, NE
Wake Forest University
Winston Salem, NC

Press Releases & Society Meetings

October 2021

Cicero Diagnostics Reaches 10,000-patient milestone with its ReceptivaDx Test

September 2021

Cicero Diagnostics to Partner with Mediaplanet a Second Time in a Campaign to Educate Women Contemplating IVF About its ReceptivaDX Test

June 2021

Cicero Diagnostics Introduces Fertility App for ReceptivaDx

May 2021

Cicero Diagnostics Hits Record Growth for First Quarter 2021

October 2020

Cicero Diagnostics Announces its Scientific Advisor, Dr. Bruce Lessey, Will Be Featured at The Endometriosis Summit Event During Virtual Fertility Weekend Demand

September 2020

Fertility and Sterility Publishes Largest Outcomes Research to Date on Cicero Diagnostic’s BCL6 Protein Test for Unexplained Infertility Demand

February 2020

Cicero Diagnostics Awarded $1 Million NIH Grant to Further Research on Markers for Unexplained Infertility, Failed Implantation and Recurrent Pregnancy Loss

February 2018

ReceptivaDx™ Test Now Being Used by over 150 IVF Centers Nationwide; Cicero Diagnostics, Inc. Adds Second US Laboratory Site to Meet Demand

November 2017

BusinessWire.com – BCL6 Biomarker Predicts IVF Success and Failure in Pivotal Study

June 2017

‘Breakthrough’ Test for Unexplained Infertility Now Available

March 2023

Pacific Society for Reproductive Medicine (PSRM)
March 12-14, 2023
Sydney, Australia

March 2023

Pacific Coast Reproductive Society (PCRS)
March 22-26, 2023
Indian Wells, CA

June 2023

Midwest Reproductive Symposium International (MRSI)
June 7-10, 2023
Chicago, IL

June 2023

European Society of Human Reproduction and Embryology (ESHRE)
June 25-28, 2023
Copenhagen, Denmark

October 2023

American Society of Reproductive Medicine (ASRM)
October 14-18, 2023
New Orleans, LA

About Us

OVERVIEW
Cicero Diagnostics is a women’s health care company founded in October 2014. It is dedicated to the advancement of clinical assays for understudied women’s diseases primarily in the area of infertility. Its current testing platforms, under the brand ReceptivaDx™ , include several biomarkers highly associated with inflammation on the uterine lining most often diagnosed as endometriosis. The company has over 300 IVF centers from around the world using their services and continues to establish new clients weekly.
Our team

Chris Jackson

Chief Executive Officer & Founder

Chris Jackson has been in diagnostic lab testing for over 30 years focusing on health care sales and marketing. Mr. Jackson has launched over 35 products during his career, with the majority in the field of women’s health & reproductive medicine.

From 1998-2006, Chris was National Sales Director of US sales for Adeza biomedical. Adeza’s key product was an assay known as Fetal Fibronectin, used by OBGYN’s to identify women at risk of preterm birth. He took the company from $2M in sales in 1998 to $45M in 2006. In 2004, the company had a successful IPO and was eventually purchased but Cytech (now Hologic) in 2007. From his experience at Adeza and his deep understanding of Women’s Health, Chris started Cicero Diagnostics after negotiating exclusive rights to a unique biomarker highly associated with endometriosis and infertility held by the University of North Carolina. Since Cicero Diagnostics launch in 2017, the company has seen explosive growth in test use, research publications and a million dollar NIH small business (SBIR) grant. In addition, ReceptivaDx’s growing social media presence has provided access to  educational information on the value of the test across multiple channels worldwide.

Dan Angress

Chief Operating Officer

Mr. Angress has over 30 years experience in diagnostic medicine focused on commercialization and operations . He has overseen multiple labs in various executive capacities including business development, marketing, customer service, product management, and operations. His breadth of knowledge in women’s health and reproductive medicine covers a wide range of areas. Mr. Angress serves as the scientific liaison for the company including principal investigator on Cicero’s SBIR NIH grants.

Bruce Lessey, M.D., PHD.

Scientific Advisor - Wake Forest University

Dr. Lessey is the Scientific Advisor for Cicero Diagnostics, Inc. and is an internationally recognized leader in uterine receptivity research and the identification of markers associated with unexplained infertility. Dr. Lessey’s extensive research background includes published research on Beta 3 Integrin and BCL6, the two key components of the current ReceptivaDxTM Assay. He has served on multiple editorial boards for major journals and published over 150 peer reviewed articles, with a focus on infertility, endometriosis and the role of the endometrium in embryo implantation.

David Schammel, M.D.

Pathologist and Partner at Pathology Associates - Greensville, SC

Dr. David Schammel is the lead pathologist for all ReceptivaDxTM testing for Cicero Diagnostics, Inc. . Dr. Schammel, a partner of Pathology Associates in Greenville, SC, has been involved with uterine receptivity testing for over 10 years. Dr. Schammel currently serves as the Medical Director for Pathology Consultants, Inc and is based at the main campus of the Greenville Health System in Greenville, SC.

Licenses & Proprietary Technologies

Cicero Diagnostics currently holds the exclusive rights to market and sell the patent protected markers used in the ReceptivaDx™ testing platform. Patents are held by the University of North Carolina. Additional markers under research evaluation are also held as options by the company.

Research Affiliations & NIH Grants

Cicero Diagnostics is currently involved with additional research studies having been awarded an SBIR Fast Track grant from the NIH in January of 2019. This 3 year grant allows Cicero to continue to validate what has currently been published on the biomarkers’ value in predicting endometriosis as the source of a women’s unexplained infertility. Other published papers have demonstrated the success of follow-up treatment leading to more live births for previously failed IVF patients. Using Wake Forest Medical Center, University of North Carolina, Clemson University and Stanford University, Cicero Diagnostics will conduct additional studies to supplement and support these findings.

Cicero FCOI Policy 2

Lab Locations

Cicero currently uses three laboratory sites for our testing. Both sites have expertise in Anatomic pathology and specific expertise in these Immunohistochemistry bio-markers:

Northwest Pathology

3614 Meridian Street, #100
Bellingham, WA 98225
CLIA:# 50D1017935

Pathology Consultants Inc

8 Memorial Court, Suite 1
Greenville, SC 29605
CLIA:# 4200252365

Pathline LLC

535 E. Crescent Ave
Ramsey, NJ 07446
CLIA:# 31D2050001

Contact Us

Please fill out the form below and we’ll contact you soon!

Contact Info

Customer Service Phone:
(800) 795-5385 or (657) 261-6740

Chris Jackson
[email protected]

Dan Angress
[email protected]

Email:
[email protected]

Corporate Office:
Cicero Diagnostics
2538 Anthem Village Drive #105
Henderson, NV 89052

Phone
(800) 795-5385

Email
[email protected]

Navigation

  • Home
  • Products & Services Offered
  • Clinical Data & Research
  • Media
  • About Us
  • Contact Us
  • Home
  • Products & Services Offered
  • Clinical Data & Research
  • Media
  • About Us
  • Contact Us
© 2020 Cicero Diagnostics | Privacy Policy